Loading publications…
The last 5 uploaded publications
Assessment of the Tolerability and Optimal Dosing of the Combination of Brentuximab Vedotin and Lenalidomide in Patients With Relapsed or Refractory T‐cell Lymphoma: Results of a Single‐centre Phase 1 Dose‐escalation Study
Carrie Van Der Weyden, Mathias Bressel, Amit Khot, H. Miles Prince, Michael Dickinson (2025). Assessment of the Tolerability and Optimal Dosing of the Combination of Brentuximab Vedotin and Lenalidomide in Patients With Relapsed or Refractory T‐cell Lymphoma: Results of a Single‐centre Phase 1 Dose‐escalation Study. , 6(3), DOI: https://doi.org/10.1002/jha2.70033.
Article63 days agoAllogeneic stem cell transplantation achieves long-term remissions in mantle cell lymphoma, including in <i>TP53</i> -mutated disease
Thomas E. Lew, Edward R. Scheffer Cliff, Michael Dickinson, Constantine S. Tam, John F. Seymour, Piers Blombery, Ashish Bajel, David Ritchie, Amit Khot (2023). Allogeneic stem cell transplantation achieves long-term remissions in mantle cell lymphoma, including in <i>TP53</i> -mutated disease. , 64(11), DOI: https://doi.org/10.1080/10428194.2023.2241095.
Article63 days agoTreatment approaches for patients with TP53-mutated mantle cell lymphoma
Thomas E. Lew, Adrian Minson, Michael Dickinson, Sasanka M. Handunnetti, Piers Blombery, Amit Khot, Mary Ann Anderson, David Ritchie, Constantine S. Tam, John F. Seymour (2023). Treatment approaches for patients with TP53-mutated mantle cell lymphoma. , 10(2), DOI: https://doi.org/10.1016/s2352-3026(22)00355-6.
Article63 days agoCAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study
Adrian Minson, Nada Hamad, Chan Y. Cheah, Constantine S. Tam, Piers Blombery, David Westerman, David Ritchie, Huw Morgan, Nicholas Holzwart, Stephen Lade, Mary Ann Anderson, Amit Khot, John F. Seymour, Molly Robertson, Imogen Caldwell, Georgina L. Ryland, Javad Saghebi, Zahra Sabahi, Jing Xie, Rachel Koldej, Michael Dickinson (2023). CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study. , 143(8), DOI: https://doi.org/10.1182/blood.2023021306.
Article63 days agoTime-Limited Ibrutinib and Tisagenlecleucel Is Highly Effective in the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma, Including Those with <i>TP53</i> Mutated and Btki-Refractory Disease: First Report of the Tarmac Study
Adrian Minson, Nada Hamad, Chan Y. Cheah, Constantine S. Tam, Piers Blombery, David Westerman, Stephen Lade, David Ritchie, Rachel Koldej, Mary Ann Anderson, Amit Khot, John F. Seymour, Molly Robertson, Imogen Caldwell, Georgina L. Ryland, Jing Xie, Huw Morgan, Michael Dickinson (2022). Time-Limited Ibrutinib and Tisagenlecleucel Is Highly Effective in the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma, Including Those with <i>TP53</i> Mutated and Btki-Refractory Disease: First Report of the Tarmac Study. , 140(Supplement 1), DOI: https://doi.org/10.1182/blood-2022-160459.
Article63 days ago